UNSPSC 51292914: Tiracizine

This classification denotes an antiarrhythmic agent with the molecular formula C21H25N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9UUO2T61K7, chemically known as ethyl 5-(n,n-dimethylglycyl)-10,11-dihydro-5h-dibenz(b,f)azepine-3-carbamate but generally known as tiracizine, which bears US NIH Compound Identifier 71264. European Medicines Agency schedules Tiracizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11114MIG.

UNSPSC 51292914 Tiracizine, a Commodity code, does not align with the recent state and local solicitation activity posted under this designation. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are tiracizine or closely related pharmaceutical compounds. The code shows little relevant recent activity, and the mismatch between the code's nominal scope and the opportunities tagged to it suggests either incorrect code assignment in the procurement records or that tiracizine itself does not feature prominently in current state and local health and human services purchasing.

The opportunities that do appear under this code span different issuing bodies and geographic regions. Seminole County, Florida released an IFB on June 30, 2026 (response due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities including Oregon. Activity spans Florida, Texas, Minnesota, and Oregon, but the pharmaceutical products actually being procured do not match the tiracizine code designation.